BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 20721603)

  • 1. Nanoparticle delivery systems in cancer vaccines.
    Krishnamachari Y; Geary SM; Lemke CD; Salem AK
    Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy and nanomedicine.
    Sheng WY; Huang L
    Pharm Res; 2011 Feb; 28(2):200-14. PubMed ID: 20821040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gold nanoparticle mediated cancer immunotherapy.
    Almeida JP; Figueroa ER; Drezek RA
    Nanomedicine; 2014 Apr; 10(3):503-14. PubMed ID: 24103304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy.
    Nguyen TL; Choi Y; Kim J
    Adv Mater; 2019 Aug; 31(34):e1803953. PubMed ID: 30417454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Particulate carrier systems as adjuvants for cancer vaccines.
    Saung MT; Ke X; Howard GP; Zheng L; Mao HQ
    Biomater Sci; 2019 Nov; 7(12):4873-4887. PubMed ID: 31528923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
    Klippstein R; Pozo D
    Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-based immunotherapy for cancer.
    Shao K; Singha S; Clemente-Casares X; Tsai S; Yang Y; Santamaria P
    ACS Nano; 2015 Jan; 9(1):16-30. PubMed ID: 25469470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
    Hamdy S; Haddadi A; Hung RW; Lavasanifar A
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 13. Engineering the immune system with particles, step-by-step.
    De Geest BG
    Mol Immunol; 2018 Jun; 98():25-27. PubMed ID: 29526503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
    Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
    Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
    Rhodes KR; Green JJ
    Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Cancer Vaccination by In Situ Nanomicelle-Generating Dissolving Microneedles.
    Kim NW; Kim SY; Lee JE; Yin Y; Lee JH; Lim SY; Kim ES; Duong HTT; Kim HK; Kim S; Kim JE; Lee DS; Kim J; Lee MS; Lim YT; Jeong JH
    ACS Nano; 2018 Oct; 12(10):9702-9713. PubMed ID: 30141896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanovaccines for cancer immunotherapy.
    Zhang Y; Lin S; Wang XY; Zhu G
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response.
    Yu X; Dai Y; Zhao Y; Qi S; Liu L; Lu L; Luo Q; Zhang Z
    Nat Commun; 2020 Feb; 11(1):1110. PubMed ID: 32111828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility.
    Van Nuffel AMT; Boudousquié C; Tuyaerts S
    Front Immunol; 2019; 10():2032. PubMed ID: 31507617
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
    Zhu G; Zhang F; Ni Q; Niu G; Chen X
    ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.